Vertex completes rolling BLA submission for povetacicept after positive Phase 3 IgAN data
Vertex completed the rolling BLA submission for povetacicept in IgA nephropathy after positive Phase 3 RAINIER interim data. The company plans to use a Priority Review Voucher to accelerate FDA review.
Vertex completed the rolling BLA submission for U.S. accelerated approval of povetacicept in IgA nephropathy and plans to utilize a Priority Review Voucher to accelerate U.S. Food and Drug Administration review. Positive Week 36 interim data from the Phase 3 RAINIER trial demonstrated that povetacicept met its primary endpoint by achieving a significant reduction in proteinuria in adults with IgA nephropathy compared to placebo and met all key secondary endpoints.
The trial also showcased a substantial reduction in disease-driving antibodies and resolution of hematuria, alongside a generally favorable safety and tolerability profile. The FDA has granted Fast Track designation for the program.
In its first quarter 2026 financial results, Vertex said the povetacicept program continues rapid advancement. The company said it intended to complete its Biologics License Application for povetacicept by the end of March, which could potentially lead to an accelerated approval by late 2026.
Vertex reported total revenue increased 8% in the first quarter of 2026. The company also said it was off to a strong start in 2026, driven by leadership in cystic fibrosis; growth in sickle cell disease, beta thalassemia, and acute pain; as well as rapid pipeline progress.